Pay in 4 interest-free payments of $5.20 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Key Takeaways Triple agonist mechanism: Retatrutide is the first medication to activate GIP, GLP-1, and glucagon receptors simultaneously GLP-1 component reduces appetite and slows gastric emptying, the core appetite suppression pathway GIP component improves insulin sensitivity and promotes favorable fat distribution Glucagon component increases energy expenditure through thermogenesis and promotes fat breakdown Weight loss: Phase 2 trials showed up to 24.2% weight loss at 48 weeks, compared to tirzepatide (~22%) and semaglutide (~15%) Investigational status: Not FDA-approved
Glucagon-like peptide-1 receptor agonist (GLP-1RA) is a relatively safe and effective hypoglycemic drug that was newly discovered in recent years
Health Canada says many generic medications are 45 to 90 per cent cheaper than brand-name versions, a benchmark now drawing fresh attention after the regulator cleared two generic semaglutide injections referencing Ozempic within roughly a week
monitor weekly
Medication Interactions: Certain medications, like proton pump inhibitors and metformin, may interfere with B12 absorption
